Curated News
By: NewsRamp Editorial Staff
October 15, 2026
HeartBeam Joins EU-Funded EXIT-CVD to Study Portable ECG
TLDR
- HeartBeam joins EU's EXIT-CVD initiative, leading HEART-CHECK study to validate its portable ECG system and gain advantage in cardiac monitoring.
- HeartBeam's 3D ECG technology collects signals from three directions, synthesizes a 12-lead ECG, and will be tested in 22 studies across 17 countries.
- HeartBeam's portable ECG system aims to detect heart attacks at home, potentially saving lives and improving cardiac care for high-risk patients.
- HeartBeam's cable-free 3D ECG technology, already FDA-cleared for arrhythmia, is now being tested in a massive European study with 14,000 patients.
Impact - Why it Matters
This news underscores the growing importance of decentralized cardiac care and early detection technologies. Heart attack and acute coronary syndrome remain leading causes of death worldwide, and many patients face high risk of recurrence after discharge. HeartBeam’s portable 3D ECG system could enable timely intervention outside hospitals, potentially saving lives and reducing healthcare costs. Participation in a large EU-funded consortium validates the technology and provides robust clinical evidence that could accelerate adoption and regulatory approvals. For investors, this collaboration highlights HeartBeam’s strategic positioning in the cardiac monitoring market and its potential to capture a significant share of the expanding remote patient monitoring sector. As cardiovascular diseases continue to burden healthcare systems globally, innovations like HeartBeam’s are critical to improving outcomes and efficiency.
Summary
HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care, has joined EXIT-CVD, a major European cardiovascular research initiative co-funded by the European Union Innovative Health Initiative and industry partners. Led by University Medical Center Groningen and Royal Philips, the consortium unites 42 organizations across 17 countries to conduct 22 clinical studies involving over 14,000 patients, with a total budget of 27.6 million euros. As a contributing partner, HeartBeam will lead the HEART-CHECK study to evaluate its portable electrocardiogram (ECG) system for early detection and triage of cardiac events in high-risk patients recently discharged after acute coronary syndrome. The study will assess the system's clinical performance and integration into real-world care pathways.
The HeartBeam System recently received U.S. Food and Drug Administration Breakthrough Device Designation for at-home heart attack assessment, though this application remains investigational. HeartBeam is dedicated to transforming the detection and monitoring of critical cardiac conditions. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility, redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement.
For investors, the latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT. The announcement was distributed by InvestorWire, a specialized communications platform for advanced wire-grade press release syndication, part of the Dynamic Brand Portfolio @ IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam Joins EU-Funded EXIT-CVD to Study Portable ECG
